

Table SI. Bile acid information.

Compound	Company	Cat. No.	Solvent	Molecular weight, g/mol	Stock concentration, mM	Working concentration, μ M
Cholic acid	Sigma-Aldrich	C9377	DMSO	408.57	100	100
Chenodeoxycholic acid	Sigma-Aldrich	C1192	DMSO	392.57	25.5	100
Taurocholic acid	Sigma-Aldrich	T4009	Ethanol	515.70	18.6	100
Glycochenodeoxycholic acid	Sigma-Aldrich	G0759	Ethanol	449.62	5.3	100

Table SII. Baseline characteristics

Parameter	Controls (n=20)	Patients with early gastric cancer (n=19)	P-value
Age, mean±SD	50.0±12.6	63.0±13.2	<0.001
Male, n (%)	13 (65.0)	13 (68.4)	1.000
Hypertension, n (%)	2 (10.0)	6 (31.6)	0.127
Diabetes, n (%)	2 (10.0)	4 (21.1)	0.407
Cholecystectomy, n (%)	0 (0.0)	1 (5.3)	0.487
Infection of <i>H. pylori</i>	7 (35.0)	10 (52.6)	
^a Atrophic gastritis with intestinal metaplasia, n (%)	8 (40.0)	15 (78.9)	0.022

^aBackground histological manifestation. SD, standard deviation; *H. pylori*, *Helicobacter pylori*